Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C. Widemann, John P. Perentesis, Eva Dombi et al.|Sarcoma|2019Cited by 74
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell deathWenjing Qin, Angela C. Hirbe|Cancer Medicine|2019Cited by 25
<i>Ex vivo</i> to <i>in vivo</i> model of malignant peripheral nerve sheath tumors for precision oncologyAlex T. Larsson, Angela C. Hirbe|Neuro-Oncology|2023Cited by 17
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective AnalysisLawrence Liu, Angela C. Hirbe, Carina Dehner et al.|Genes|2022Cited by 13
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1Abigail Godec, Angela C. Hirbe|Neuro-Oncology Advances|2019Cited by 6